// App-Quantinova.ai

CT113 : A phase III, multicenter, randomized study evaluating the efficacy and safety and efficacy of erythrocyte encapsulated l-asparaginase (Ery001) versus native l-asparaginase (L-asp) in combination with COOPRALL regimen in patients with first relapse of acute lymphoblastic leukemia

Researchers

Presenter

  • Yves Bertrand

Principal Investigators

  • Andre Baruchel

  • Xavier Thomas

  • Nicolas Blin

  • Emmanuelle Tavernier

  • Yves Perel

  • Norbert Vey

  • Virginie Gandemer

  • Iman El Hariry

  • Yann Godfrin

Medical Centers

  • GFPC (France), Institut de Cancerologie de la Loire, St. Priest En Jarez, France

  • Pediatric Radiology Unit - Hospices Civils de Lyon, Lyon, France

  • Centre Hospitalier Lyon-Sud, Pierre-Benite, France

  • Institut Paoli-Calmettes, Marseille, France

  • Hopital des Enfants - Hopital Pellegrin, Bordeaux, France

  • Pediatric Hematology, Robert Debre Hospital - APHP and University Paris Diderot, Paris, France

Locations

  • France

Companies

  • Erytech Pharma Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Asparaginase

  • ERY001

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved